NEWARK, Calif., Oct. 18, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced it has retained Eliseo Oreste Salinas, MD, MSc, on an exclusive basis, to help formulate and execute the clinical translation and product development strategy for the Company's proprietary HuCNS-SC® cells (purified human neural stem cells). Dr. Salinas was most recently Executive Vice President, Head of Development and Chief Medical Officer at Elan Pharmaceuticals. He has extensive experience and expertise developing therapeutic products for central nervous system (CNS) disorders in many key jurisdictions worldwide, including the United States, Canada, the European Union, and Japan.
StemCells, Inc. Adds Eliseo Salinas To Advise On Product Development Strategy For Its Proprietary Human Neural Stem Cells
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts